CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies (Q38832599)

6 September 2017

title

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies (English)

1 reference

6 September 2017

1 reference

C J Turtle

1

1 reference

6 September 2017

S R Riddell

series ordinal

2

1 reference

6 September 2017

D G Maloney

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

12 May 2016

1 reference

Clinical Pharmacology & Therapeutics

6 September 2017

published in

1 reference

6 September 2017

volume

100

1 reference

6 September 2017

issue

3

1 reference

6 September 2017

page(s)

252-258

1 reference

CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor modified T cell therapy for B cell malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Current concepts in the diagnosis and management of cytokine release syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

A human memory T cell subset with stem cell-like properties

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCPT.392

7 January 2021

Identifiers

DOI

10.1002/CPT.392

1 reference

6 September 2017

1 reference